Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Eliquis and Opdivo sales reach $1.5 billion in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
1Q Revenues: $5.2 billion (+5%)
1Q Earnings: $1.5 billion (-2%)
Comments: Eliquis sales were up 37% to $1.5 billion in the quarter. Opdivo sales were up 34% to $1.5 billion. Orencia sales were up 11% to $593 million. Sprycel sales were down 5% to $438 million. Yervoy sales were down 25% to $249 million. Established product sales were down including: Baraclude, down 20% to $225 million, the Sustiva Franchise, down 54% to $84 million, the Reyataz Franchise down 36% to $124 million, and the Hepatitis C Franchise, down 98% to $3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters